The press program for the 2017 Annual Meeting of the American Society for Radiation Oncology (ASTRO) will feature advances in cancer research, including reports from phase II and III clinical trials. Studies that examine innovative treatments, such as immunotherapy, mental health influences on cancer outcomes and optimal radiation dosing and sequencing, will also be presented at the largest meeting for the field of radiation oncology.
The meeting, which is expected to attract more than 11,000 attendees, will be held September 24 – 27, 2017, at the San Diego Convention Center. Researchers selected for the press program will share their findings in a series of news briefings held in room 24C and webcast live to registered press (register today!). The schedule is as follows:
The Science of Radiation Oncology: Innovative Approaches
Ad Statistics
Times Displayed: 112448
Times Visited: 6718 MIT labs, experts in Multi-Vendor component level repair of: MRI Coils, RF amplifiers, Gradient Amplifiers Contrast Media Injectors. System repairs, sub-assembly repairs, component level repairs, refurbish/calibrate. info@mitlabsusa.com/+1 (305) 470-8013
Sunday, September 24, 1:00 – 2:00 p.m. Pacific time
“Consolidative radiotherapy for limited metastatic non-small cell lung cancer: A randomized phase II trial,” Puneeth Iyengar, MD, PhD, University of Texas Southwestern (Abstract LBA-3)
“Phase II 5-arm trial of ipilimumab plus lung or liver stereotactic radiation for patients with advanced malignancies,” James Welsh, MD, MD Anderson Cancer Center (Abstract LBA-5)
“Novel associations between the immune landscape of prostate cancer and post-operative radiation response,” Shuang (George) Zhao, MD, MSE, University of Michigan (Abstract 3)
[invited study to be confirmed]
Moderator: Brian Czito, MD, Duke University
Quality Care in Radiation Oncology: Refining Treatments
Monday, September 25, 11:00 a.m. – 12:00 p.m. Pacific time
“A phase III trial of pelvic radiation therapy versus vaginal cuff brachytherapy followed by paclitaxel/carboplatin chemotherapy in patients with high-risk, early-stage endometrial cancer: A Gynecology Oncology Group study,” Marcus Randall, MD, FASTRO, University of Kentucky (Abstract LBA-1)
“Two-year results for MC1273, a phase II evaluation of aggressive dose de-escalation for adjuvant chemoradiation in HPV+ oropharynx squamous cell carcinoma (OPSCC),” Daniel Ma, MD, Mayo Clinic (Abstract LBA-14)
“Hypofractionated radiation therapy after mastectomy for the treatment of high-risk breast cancer: Five-year follow-up result of a randomized trial,” Shulian Wang, MD, Chinese Academy of Medical Sciences and Peking Union Medical College (Abstract 5)
“Long-term results of RTOG 0617: A randomized phase III comparison of standard dose versus high dose conformal chemoradiotherapy +/- cetuximab for stage III NSCLC,” Jeffrey Bradley, MD, FASTRO, Washington University at St. Louis (Abstract 227)
